Ranze Oliver, Hofmann Erich, Distelrath Andrea, Hoeffkes Heinz-Gert
Tumorklinik, Klinikum Fulda, Germany.
Onkologie. 2007 Sep;30(8-9):450-1. doi: 10.1159/000105131. Epub 2007 Sep 7.
Sorafenib has been approved in the U.S. and the European Union for patients with advanced renal cell cancer (RCC). There is evidence that treatment with sorafenib can achieve partial remissions in patients with brain metastases of RCC.
We report of a patient with leptomeningeal carcinomatosis of RCC, who 10 days after initiation of sorafenib therapy showed a noticeable decrease in contrast enhancement of the tumor in a magnetic resonance imaging (MRI) scan of the brain. This partial response was verified by an MRI scan on day 74.
Results of a sub-evalution of a randomized phase III trial show that sorafenib offers encouraging activity in the treatment of patients with RCC and brain metastases.
This case shows that sorafenib can achieve rapid tumor response in a patient with leptomeningeal carcinomatosis of RCC. This partial remission can persist for at least 10 weeks.
索拉非尼已在美国和欧盟被批准用于晚期肾细胞癌（RCC）患者。有证据表明，索拉非尼治疗可使RCC脑转移患者获得部分缓解。
我们报告了1例RCC软脑膜癌病患者，在开始索拉非尼治疗10天后，脑部磁共振成像（MRI）扫描显示肿瘤对比增强明显降低。在第74天的MRI扫描证实了这种部分缓解。
一项随机III期试验的亚评估结果显示，索拉非尼在治疗RCC和脑转移患者方面具有令人鼓舞的活性。
该病例表明，索拉非尼可使1例RCC软脑膜癌病患者的肿瘤迅速产生反应。这种部分缓解至少可持续10周。
